Page 1 of Clinical Trials for Drug bortezomib, 621 Total Matches

Show/Hide Clinical Trials Which are Not Seeking New Volunteers

1
Terminated
Preemptive Strike With Bortezomib in Multiple Myeloma Patients
Last Updated: June 13, 2011
Condition(s): Multiple Myeloma
2
Recruiting
Impact of Proteasome Inhibition on Anti-Donor HLA Antibody Production After Kidney Transplantation
Last Updated: December 5, 2011
Condition(s): Disorder of Transplanted Kidney; Donor Specific Alloantibodies
3
Recruiting
The Impact of Velcade(TM)on Antibody Secreting Cells in Sensitized Renal Allograft Candidates
Last Updated: January 18, 2012
Condition(s): Kidney Transplant
4
Recruiting
Natural Killer Cells and Bortezomib to Treat Cancer
Last Updated: May 3, 2012
Condition(s): Lung or Prostatic Neoplasms; Colorectal or Kidney Neoplasms; Pancreatic Neoplasms; Leukemia, Myelogenous, Chronic Lymphocytic Leukemia, BCR-ABL Positive; Melanoma; CLL
5
Not yet recruiting
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study
Last Updated: May 20, 2011
Condition(s): Non-Hodgkin Lymphoma
6
Recruiting
Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis
Last Updated: January 9, 2012
Condition(s): Amyloidosis
7
Recruiting
Bortezomib Plus Rituximab for EBV+ PTLD
Last Updated: February 10, 2012
Condition(s): Post-transplant Lymphoproliferative Disease; Solid Organ Transplant; Stem Cell Transplant (Bone Marrow Transplant); Epstein Barr Virus Infections
8
Recruiting
Bortezomib and Midostaurin With or Without Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Last Updated: November 10, 2011
Condition(s): Acute Myeloid Leukemia; Acute Myeloid Leukemia With Multilineage Dysplasia Following; Myelodysplastic Syndrome; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Recurrent Adult Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia
9
Recruiting
Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Last Updated: April 18, 2012
Condition(s): Indolent Non-Hodgkin's Lymphoma; Chronic Lymphocytic Leukemia; Mantle Cell Lymphoma
10
Recruiting
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Last Updated: June 7, 2011
Condition(s): Multiple Myeloma, Plasma Cell Leukemia
11
Active, not recruiting
Phase II Avastin + Bortezomib for Patients With Recurrent Malignant Glioma
Last Updated: February 17, 2012
Condition(s): Glioblastoma; Gliosarcoma
12
Completed
An Extension Study to Provide Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma Who Previously Participated in a Bortezomib Phase I/II Study and Who May Benefit From Re-Treatment With or Continuation of Bortezomib Therapy
Last Updated: May 16, 2011
Condition(s): Multiple Myeloma
13
Terminated
A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma
Last Updated: May 3, 2012
Condition(s): Relapsed or Refractory Multiple Myeloma
14
Recruiting
Multicenter Clinical Trial to Investigate the Efficacy and Safety of Bendamustine, Dexamethasone and Thalidomide in Relapsed or Refractory Multiple Myeloma Patients After Treatment With Lenalidomide and Bortezomib or Which Are Ineligible to One of These Drugs
Last Updated: February 3, 2012
Condition(s): Multiple Myeloma
15
Terminated
SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715AM2)(TERMINATED)
Last Updated: May 9, 2012
Condition(s): Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell
16
Active, not recruiting
Safety and Efficacy of RAD001 in Patients With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy.
Last Updated: March 9, 2012
Condition(s): Lymphoma, Mantle- Cell
17
Active, not recruiting
Study of Vorinostat (MK-0683) an HDAC Inhibitor, or Placebo in Combination With Bortezomib in Patients With Multiple Myeloma (MK-0683-088 AMJ)
Last Updated: October 11, 2011
Condition(s): Multiple Myeloma
18
Recruiting
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Last Updated: January 11, 2012
Condition(s): Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)
19
Not yet recruiting
Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment
Last Updated: March 7, 2012
Condition(s): Multiple Myeloma
20
Completed
Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients
Last Updated: April 12, 2012
Condition(s): Multiple Myeloma

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is: http://clinicaltrialsfeeds.org/clinical-trials/results/?term=Drug+bortezomib

Page 1 of Clinical Trials for Drug bortezomib, 621 Total Matches

Get the Latest Results via Email or RSS

Subscribe via Web Newsreaders

Browse

Clinical Trials Background

About